Hanall Biopharma Co., Ltd. (KRX:009420)
South Korea
· Delayed Price · Currency is KRW 27,250
-250 (-0.91%)
Apr 18, 2025, 3:30 PM KST
Hanall Biopharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 138,944 | 134,910 | 109,995 | 101,594 | 88,602 | Upgrade
|
| Other Revenue | - | -0 | -0 | -0 | - | Upgrade
|
| Revenue | 138,944 | 134,910 | 109,995 | 101,594 | 88,602 | Upgrade
|
| Revenue Growth (YoY) | 2.99% | 22.65% | 8.27% | 14.66% | -18.30% | Upgrade
|
| Cost of Revenue | 65,738 | 59,870 | 48,120 | 41,364 | 38,027 | Upgrade
|
| Gross Profit | 73,206 | 75,040 | 61,876 | 60,231 | 50,575 | Upgrade
|
| Selling, General & Admin | 51,850 | 47,520 | 42,586 | 38,472 | 34,264 | Upgrade
|
| Research & Development | 19,993 | 23,945 | 16,498 | 10,462 | 9,316 | Upgrade
|
| Other Operating Expenses | 660.34 | 669.45 | 584.09 | 605.75 | 541.03 | Upgrade
|
| Operating Expenses | 72,975 | 73,296 | 60,370 | 50,132 | 44,640 | Upgrade
|
| Operating Income | 230.47 | 1,743 | 1,506 | 10,099 | 5,935 | Upgrade
|
| Interest Expense | -70.97 | -63.86 | -21.88 | -25.48 | -16.01 | Upgrade
|
| Interest & Investment Income | 490.32 | 1,227 | 1,427 | 719.84 | 2,145 | Upgrade
|
| Earnings From Equity Investments | -99.53 | -62.12 | -45.39 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -408.83 | 349.6 | -600.15 | -115.94 | 82.78 | Upgrade
|
| Other Non Operating Income (Expenses) | -203.55 | -1,067 | -228.48 | -745.87 | 11,138 | Upgrade
|
| EBT Excluding Unusual Items | -62.07 | 2,127 | 2,037 | 9,932 | 19,284 | Upgrade
|
| Gain (Loss) on Sale of Investments | 331.43 | 1,121 | -124.34 | -177.44 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -452.56 | -9.32 | 16.99 | -1,052 | -14.29 | Upgrade
|
| Asset Writedown | - | -36.72 | - | - | -44.82 | Upgrade
|
| Pretax Income | -183.2 | 3,203 | 1,929 | 8,702 | 19,225 | Upgrade
|
| Income Tax Expense | 1,622 | -306.08 | 1,678 | -194.05 | -539.21 | Upgrade
|
| Net Income | -1,805 | 3,509 | 251.47 | 8,896 | 19,765 | Upgrade
|
| Net Income to Common | -1,805 | 3,509 | 251.47 | 8,896 | 19,765 | Upgrade
|
| Net Income Growth | - | 1295.23% | -97.17% | -54.99% | 3.08% | Upgrade
|
| Shares Outstanding (Basic) | 51 | 51 | 51 | 51 | 51 | Upgrade
|
| Shares Outstanding (Diluted) | 51 | 51 | 51 | 51 | 51 | Upgrade
|
| Shares Change (YoY) | 0.04% | -0.24% | -0.76% | 0.05% | 0.00% | Upgrade
|
| EPS (Basic) | -35.59 | 69.21 | 4.95 | 173.74 | 386.19 | Upgrade
|
| EPS (Diluted) | -35.59 | 69.21 | 4.95 | 173.74 | 386.19 | Upgrade
|
| EPS Growth | - | 1298.63% | -97.15% | -55.01% | 3.08% | Upgrade
|
| Free Cash Flow | 7,718 | 27,231 | 22,434 | -3,766 | -1,633 | Upgrade
|
| Free Cash Flow Per Share | 152.20 | 537.18 | 441.48 | -73.55 | -31.91 | Upgrade
|
| Gross Margin | 52.69% | 55.62% | 56.25% | 59.29% | 57.08% | Upgrade
|
| Operating Margin | 0.17% | 1.29% | 1.37% | 9.94% | 6.70% | Upgrade
|
| Profit Margin | -1.30% | 2.60% | 0.23% | 8.76% | 22.31% | Upgrade
|
| Free Cash Flow Margin | 5.56% | 20.18% | 20.39% | -3.71% | -1.84% | Upgrade
|
| EBITDA | 3,351 | 4,990 | 4,558 | 12,824 | 8,829 | Upgrade
|
| EBITDA Margin | 2.41% | 3.70% | 4.14% | 12.62% | 9.96% | Upgrade
|
| D&A For EBITDA | 3,121 | 3,247 | 3,053 | 2,725 | 2,894 | Upgrade
|
| EBIT | 230.47 | 1,743 | 1,506 | 10,099 | 5,935 | Upgrade
|
| EBIT Margin | 0.17% | 1.29% | 1.37% | 9.94% | 6.70% | Upgrade
|
| Effective Tax Rate | - | - | 86.97% | - | - | Upgrade
|
| Advertising Expenses | 3,230 | 3,287 | 3,090 | 2,112 | 1,889 | Upgrade
|
Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.